Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors

Figure 2

Forest plots for (a) overall survival (OS), (b) progression-free survival (PFS), (c) disease control rate (DCR), and (d) immune-related adverse event (irAEs).

(a)

(b)

(c)

(d)